SHINTARO HIRATA

Last Updated :2026/01/09

Affiliations, Positions
Hiroshima University Hospital, Professor

Basic Information

Major Professional Backgrounds

  • 1998/05/06, 2000/03/31, National Hospital Organization Kure Medical Center, Clinical Resident
  • 2000/04/01, 2002/03/31, Tokyo Women's Medical University, Doctor
  • 2002/04/01, 2003/03/30, Hiroshima University, Hospital, Clinical Fellow
  • 2007/10/01, 2008/03/31, Hiroshima University, Hospital, Clinical Fellow
  • 2008/04, 2011/03, University of Occupational and Environmental Health, Japan, Assistant Professor
  • 2011/04, 2012/03, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan, Lecturer
  • 2012/04, 2015/03, University of Occupational and Environmental Health, Japan, Lecturer
  • 2015/04, 2016/08, University of Occupational and Environmental Health, Japan, Lecturer
  • 2016/09/01, 2020/03/31, Hiroshima University, Hospital, Lecturer
  • 2020/04/01, 2021/10/31, Hiroshima University, Hospital, Associate Professor
  • 2021/11/01, Hiroshima University, Hospital, Professor

Educational Backgrounds

  • Hiroshima University, Faculty of Medicine, Japan, 1992/04, 1998/03
  • Hiroshima University, Graduate School of Biomedical Sciences, Japan, 2003/04, 2009/09

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Collagenous pathology / Allergology

Research Keywords

  • Medicine, Rheumatology, Clinical Immunology, Rheumatoid Arthritis, Collagen Vascular Disease

Affiliated Academic Societies

  • Japan College of Rheumatology
  • The Japan Society for Clinical Immunology
  • The Japanese Society of Internal Medicine
  • The Japanese Society for Bone and Mineral Research
  • osteoimmunology
  • The Japan Spondyloarthritis Society
  • The Japanese Society of Inflammation and Regeneration
  • The Japanese Society for Clinical Rheumatology and Related Research
  • Japanese Society　 for　Sjogren's Syndrome
  • Japanese Society for Immunology
  • The Japanese Respiratory Society
  • Japanese Society of Allergology

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment II
  2. 2025, Undergraduate Education, Intensive, Introduction to clinical clerkship
  3. 2025, Undergraduate Education, Intensive, Practice for medical research
  4. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  5. 2025, Undergraduate Education, Intensive, Practice of Medicine II
  6. 2025, Liberal Arts Education Program1, 1Term, Introductory Seminar for First-Year Students
  7. 2025, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry
  8. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Clinical Immunology and Rheumatology
  9. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Clinical Immunology and Rheumatology
  10. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Clinical Immunology and Rheumatology
  11. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Clinical Immunology and Rheumatology

Research Activities

Academic Papers

  1. Phenotype, serotype, and data-driven clustering reveal complementary dimensions of heterogeneity in ANCA-associated vasculitis: a multicentre Japanese cohort (J-CANVAS), RHEUMATOLOGY INTERNATIONAL, 45(12), 272, 20251112
    Link to Paper Search Results by DOI
  2. Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study, IMMUNOLOGICAL MEDICINE, 48(3), 203-210, 20250703
    Link to Paper Search Results by DOI
  3. Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or polyarthritis - secondary publication, MODERN RHEUMATOLOGY, 35(5), 894-908, 202509
    Link to Paper Search Results by DOI
  4. Risk factors for cytomegalovirus reactivation during the treatment of ANCA-associated vasculitis: A retrospective cohort study of the J-CANVAS study, MODERN RHEUMATOLOGY, 35(4), 691-696, 202507
    Link to Paper Search Results by DOI
  5. Frequent detection of antinuclear antibodies and low-titre rheumatoid factor in female patients with undifferentiated peripheral spondyloarthritis in Japan: A prospective observational study, MODERN RHEUMATOLOGY, 35(4), 753-761, 202507
    Link to Paper Search Results by DOI
  6. Hsa-miR-21-5p is induced by interleukin-6 and affects multiple pathogenic factors associated with fibroblast-like synoviocytes in rheumatoid arthritis, SCIENTIFIC REPORTS, 15(1), 19416, 20250603
    Link to Paper Search Results by DOI
  7. Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry, RHEUMATOLOGY, 64(5), 2403-2410, 202505
    Link to Paper Search Results by DOI
  8. Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4, MODERN RHEUMATOLOGY, 35(3), 425-433, 202505
    Link to Paper Search Results by DOI
  9. Glucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registry, MODERN RHEUMATOLOGY, 35(3), 496-504, 202505
    Link to Paper Search Results by DOI
  10. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication, MODERN RHEUMATOLOGY, 35(3), 387-401, 202505
    Link to Paper Search Results by DOI
  11. Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study), PLOS ONE, 20(5), e0322621, 2025
    Link to Paper Search Results by DOI
  12. Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial, ANNALS OF THE RHEUMATIC DISEASES, 84(1), 41-48, 202501
    Link to Paper Search Results by DOI
  13. Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study, LUPUS SCIENCE & MEDICINE, 12(1), e001291, 20250118
    Link to Paper Search Results by DOI
  14. A Preliminary Survey of Rheumatologists on the Management of Late-onset Rheumatoid Arthritis in Japan, INTERNAL MEDICINE, 63(24), 3299-3306, 2024
    Link to Paper Search Results by DOI
  15. Effectiveness of intravenous methylprednisolone pulse in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis, RHEUMATOLOGY, 63(9), 2484-2493, 20240509
    Link to Paper Search Results by DOI
  16. Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS, CLINICAL RHEUMATOLOGY, 43(10), 3195-3204, 202410
    Link to Paper Search Results by DOI
  17. Consensus statement on the management of late-onset rheumatoid arthritis, MODERN RHEUMATOLOGY, 34(6), 1095-1102, 20240320
    Link to Paper Search Results by DOI
  18. Effectiveness of intravenous methylprednisolone pulse in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis, RHEUMATOLOGY, 63(9), 2484-2493, 20240509
    Link to Paper Search Results by DOI
  19. Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs, MODERN RHEUMATOLOGY, 34(3), 479-487, 20240328
    Link to Paper Search Results by DOI
  20. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis, JOURNAL OF BONE AND MINERAL METABOLISM, 42(2), 143-154, 202403
    Link to Paper Search Results by DOI
  21. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome, RHEUMATOLOGY, 63(8), 2056-2064, 20230911
    Link to Paper Search Results by DOI
  22. Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: Post hoc subgroup analyses of the Japanese real-world observational 'ORIGAMI' study, MODERN RHEUMATOLOGY, 34(4), 686-692, 20230901
    Link to Paper Search Results by DOI
  23. Optimal dose of intravenous cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: A retrospective cohort study of J-CANVAS, MODERN RHEUMATOLOGY, 34(4), 767-774, 20231017
    Link to Paper Search Results by DOI
  24. Disseminated Mycobacterium abscessus infection with osteoarticular manifestations as an important differential diagnosis of inflammatory arthritis: A case report and literature review, MODERN RHEUMATOLOGY CASE REPORTS, 8(1), 49-54, 20231229
    Link to Paper Search Results by DOI
  25. Association between hypogammaglobulinaemia and severe infections during induction therapy in ANCA-associated vasculitis: from J-CANVAS study, RHEUMATOLOGY, 62(12), 3924-3931, 20231201
    Link to Paper Search Results by DOI
  26. Long-Term Prognosis of Antimelanoma Differentiation-Associated Gene 5-Positive Dermatomyositis With Interstitial Lung Disease, JOURNAL OF RHEUMATOLOGY, 50(11), 1454-1461, 20231101
    Link to Paper Search Results by DOI
  27. Seasonal Influence on Development of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Conducted at Multiple Institutions in Japan ( J- CANVAS), JOURNAL OF RHEUMATOLOGY, 50(9), 1152-1158, 20230901
    Link to Paper Search Results by DOI
  28. Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling, INFLAMMATION AND REGENERATION, 43(1), 20230106
    Link to Paper Search Results by DOI
  29. Fluorodeoxyglucose-positron emission tomography/computed tomography-positive ear lesions responsive to immunosuppressive therapy in a patient with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis, MODERN RHEUMATOLOGY CASE REPORTS, 7(1), 134-137, 20230103
    Link to Paper Search Results by DOI
  30. Appearance of anti-MDA5 antibody-positive dermatomyositis after COVID-19 vaccination, MODERN RHEUMATOLOGY CASE REPORTS, 7(1), 108-112, 20230103
    Link to Paper Search Results by DOI
  31. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication, MODERN RHEUMATOLOGY, 33(1), 21-35, 20230103
    Link to Paper Search Results by DOI
  32. Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication, MODERN RHEUMATOLOGY, 33(1), 36-45, 20230103
    Link to Paper Search Results by DOI
  33. Tumor Necrosis Factor and Interleukin-1 beta Upregulate NRP2 Expression and Promote SARS-CoV-2 Proliferation, VIRUSES-BASEL, 15(7), 1498, 202307
    Link to Paper Search Results by DOI
  34. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial, LANCET RHEUMATOLOGY, 5(4), 215-224, 202304
  35. Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C, INTERNAL MEDICINE, 62(13), 1999-2004, 2023
    Link to Paper Search Results by DOI
  36. Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus, INTERNAL MEDICINE, 62(14), 2051-2057, 2023
    Link to Paper Search Results by DOI
  37. Portal Vein Thrombosis as a Cause of Undetermined Thrombocytopenia with Liver Dysfunction in a Patient with Eosinophilic Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 62(1), 123-127, 2023
    Link to Paper Search Results by DOI
  38. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome, Rheumatology (Oxford), kead425, 2023
  39. Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study, Mod Rheumatol, 2023
  40. Optimal Dose of Intravenous Cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: a retrospective cohort study of J-CANVAS, Mod Rheumatol, 2023
  41. Ameliorated nailfold capillary morphology of patients with pulmonary arterial hypertension in systemic sclerosis, treated with riociguat., Rheumatol Adv Pract, 7(1), 2023
  42. Association between increased serum IL-23 levels and ACPA positivity in patients with rheumatoid arthritis, Clin Exp Rheumatol, 41(5), 1198-1199, 2023
  43. Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design, BMC RHEUMATOLOGY, 6(1), 90-90, 20221226
    Link to Paper Search Results by DOI
  44. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
    Link to Paper Search Results by DOI
  45. Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study, RHEUMATOLOGY, 61(11), 4273-4285, 20221102
    Link to Paper Search Results by DOI
  46. Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS), ARTHRITIS RESEARCH & THERAPY, 24(1), 204, 20220823
    Link to Paper Search Results by DOI
  47. Nailfold capillaries and myositis-specific antibodies in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis, RHEUMATOLOGY, 61(5), 2006-2015, 20220505
    Link to Paper Search Results by DOI
  48. The Lipopolysaccharide Mutant Re-LPS Is a Useful Tool for Detecting LPS Contamination in Rheumatoid Synovial Cell Cultures, PATHOBIOLOGY, 89(2), 92-100, 20220322
    Link to Paper Search Results by DOI
  49. Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(2), 296-306, 20220228
    Link to Paper Search Results by DOI
  50. Patients' perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines, MODERN RHEUMATOLOGY, 32(2), 307-312, 20220228
    Link to Paper Search Results by DOI
  51. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(2), 313-322, 20220228
    Link to Paper Search Results by DOI
  52. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(1), 96-104, 20220105
    Link to Paper Search Results by DOI
  53. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(1), 74-86, 20220105
    Link to Paper Search Results by DOI
  54. Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines, MODERN RHEUMATOLOGY, 32(1), 121-126, 20220105
    Link to Paper Search Results by DOI
  55. C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids, MODERN RHEUMATOLOGY, 32(1), 141-148, 20220105
    Link to Paper Search Results by DOI
  56. Importance of anti-centromere antibodies in the diagnosis of Sjogren's syndrome, JOURNAL OF ORAL SCIENCE, 64(4), 324-326, 202210
    Link to Paper Search Results by DOI
  57. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19, JOURNAL OF CLINICAL IMMUNOLOGY, 42(7), 1360-1370, 202210
    Link to Paper Search Results by DOI
  58. N-1-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes, CYTOTECHNOLOGY, 74(4), 503-514, 202208
    Link to Paper Search Results by DOI
  59. Cancellous bone-like tissue replacement from calcinosis in patients with systemic sclerosis with multiple external root resorption, BONE REPORTS, 16, 202206
    Link to Paper Search Results by DOI
  60. Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus, Intern Med, 2022
  61. Comment on: Nailfold capillaries and myositis-specific antibodies in anti-melanoma differentiation-associated gene 5 antibody-positive DM. Reply, Rheumatology (Oxford), 61(5), e122-e124, 2022
  62. Exacerbation of systemic lupus erythematosus after receiving mRNA-1273-based coronavirus disease 2019 vaccine, J Dermatol, 49(6), e199-e200, 2022
  63. Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report, Rheumatol Adv Pract, 61(1), rkac024, 2022
  64. Bilateral facial nerve palsy responded to immunosuppressive therapy in a patient with eosinophilic granulomatosis with polyangiitis, Rheumatol Adv Pract, 6(3), rkac073, 2022
  65. Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C: A Case Report, Intern Med, 2022
  66. The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient, INTERNAL MEDICINE, 61(11), 1785-1788, 2022
    Link to Paper Search Results by DOI
  67. Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis, SCIENTIFIC REPORTS, 11(1), 20211011
    Link to Paper Search Results by DOI
  68. Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment, MODERN RHEUMATOLOGY, 31(4), 803-808, 20210704
    Link to Paper Search Results by DOI
  69. Lower CH50 as a predictor for intractable or recurrent lupus enteritis: A retrospective observational study, MODERN RHEUMATOLOGY, 31(3), 643-648, 20210504
    Link to Paper Search Results by DOI
  70. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis, MODERN RHEUMATOLOGY, 31(1), 61-69, 20210102
    Link to Paper Search Results by DOI
  71. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases, MODERN RHEUMATOLOGY, 31(1), 29-33, 20210102
    Link to Paper Search Results by DOI
  72. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 22-28, 20210102
    Link to Paper Search Results by DOI
  73. Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 95-100, 20210102
    Link to Paper Search Results by DOI
  74. Asymptomatic coronary aneurysms in a patient with eosinophilic granulomatosis with polyangiitis who developed a digital gangrene, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 130-136, 20210102
    Link to Paper Search Results by DOI
  75. The clinical characteristics and predictors of severe digital ischemia in patients with anti-aminoacyl transfer RNA synthetase antibodies, JOURNAL OF DERMATOLOGY, 48(7), 1044-1051, 202107
    Link to Paper Search Results by DOI
  76. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 202104
    Link to Paper Search Results by DOI
  77. A Rare Case of IgG4-Related Disease Presenting as a Unilateral Severe Dacryoadenitis Complicated by Hypophysitis and Hypertrophic Pachymeningitis., J Clin Rheumatol, 27, S571-S573, 2021
  78. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients, SCIENTIFIC REPORTS, 10(1), 19717, 20201112
    Link to Paper Search Results by DOI
  79. Effect ofPorphyromonas gingivalisinfection on gut dysbiosis and resultant arthritis exacerbation in mouse model, ARTHRITIS RESEARCH & THERAPY, 22(1), 20201019
    Link to Paper Search Results by DOI
  80. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study, MODERN RHEUMATOLOGY, 30(5), 799-806, 20200902
    Link to Paper Search Results by DOI
  81. Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study, MODERN RHEUMATOLOGY, 30(3), 442-449, 20200503
    Link to Paper Search Results by DOI
  82. Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD, MODERN RHEUMATOLOGY, 30(3), 551-557, 20200503
    Link to Paper Search Results by DOI
  83. Tumour necrosis factor alpha promotes secretion of 14-3-3 eta by inducing necroptosis in macrophages, ARTHRITIS RESEARCH & THERAPY, 22(1), 20200212
    Link to Paper Search Results by DOI
  84. Elevating the role of carers in rheumatoid arthritis management in the Asia-Pacific region, INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 23(7), 898-910, 202007
    Link to Paper Search Results by DOI
  85. Activin A Expressed in Rheumatoid Synovial Cells Downregulates TNF alpha-Induced CXCL10 Expression and Osteoclastogenesis, PATHOBIOLOGY, 87(3), 198-207, 202006
    Link to Paper Search Results by DOI
  86. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis, ARTHRITIS & RHEUMATOLOGY, 72(3), 488-498, 202003
    Link to Paper Search Results by DOI
  87. TGF beta 1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(3), 202002
    Link to Paper Search Results by DOI
  88. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial, ANNALS OF THE RHEUMATIC DISEASES, 79(1), 94-102, 202001
    Link to Paper Search Results by DOI
  89. Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 38(5), 956-963, 2020
  90. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 2020
    Link to Paper Search Results by DOI
  91. Predictive factors for structural remission using abatacept: Results from the ABROAD study, MODERN RHEUMATOLOGY, 29(3), 406-412, 20190504
    Link to Paper Search Results by DOI
  92. Multiple External Root Resorption of Teeth as a New Manifestation of Systemic Sclerosis-A Cross-Sectional Study in Japan, JOURNAL OF CLINICAL MEDICINE, 8(10), 1628, 201910
    Link to Paper Search Results by DOI
  93. Large-vessel vasculitis associated with PEGylated granulocyte-colony stimulating factor, NETHERLANDS JOURNAL OF MEDICINE, 77(6), 224-226, 201907
  94. Tumour necrosis factor alpha augments the inhibitory effects of CTLA-4-Ig on osteoclast generation from human monocytes via induction of CD80 expression, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 196(3), 392-402, 201906
    Link to Paper Search Results by DOI
  95. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
    Link to Paper Search Results by DOI
  96. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis, ARTHRITIS RESEARCH & THERAPY, 20(1), 240, 20181026
    Link to Paper Search Results by DOI
  97. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study, SCIENTIFIC REPORTS, 8(1), 10262, 20180706
    Link to Paper Search Results by DOI
  98. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study), ANNALS OF THE RHEUMATIC DISEASES, 77(9), 1268-1275, 201809
    Link to Paper Search Results by DOI
  99. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease, RHEUMATOLOGY, 57(3), 514-524, 201803
    Link to Paper Search Results by DOI
  100. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 36(3), 462-470, 2018
  101. Clinical practice guideline for Sjogren's syndrome 2017, MODERN RHEUMATOLOGY, 28(3), 383-408, 2018
    Link to Paper Search Results by DOI
  102. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching., Clin Immunol, 191, 67-74, 2018
  103. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus., Lupus, 27(5), 802-811, 2018
  104. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis., Rheumatology (Oxford), 57(1), 164-174, 2018
  105. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients., Ann Rheum Dis, 76(12), 1980-1985, 2017
  106. Integrating patients' perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan., Mod Rheumatol, 27(6), 924-929, 2017
  107. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease., Mod Rheumatol, 27(5), 849-854, 2017
  108. The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach, MODERN RHEUMATOLOGY, 26(2), 175-179, 2016
  109. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching, ANNALS OF THE RHEUMATIC DISEASES, 75(7), 1321-1327, 2016
  110. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study), ANNALS OF THE RHEUMATIC DISEASES, 75(11), 1917-1923, 2016
  111. Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab, MODERN RHEUMATOLOGY, 26(6), 807-812, 2016
  112. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice, MODERN RHEUMATOLOGY, 26(6), 850-856, 2016
  113. Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial, MODERN RHEUMATOLOGY, 26(6), 891-899, 2016
  114. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study., Clin Exp Rheumatol, 34(5), 834-841, 2016
  115. New assessment method in rheumatoid arthritis, Nihon Rinsho, 74(6), 931-937, 2016
  116. Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score., Nihon Rinsho Meneki Gakkai Kaishi, 39(1), 37-41, 2016
  117. ★, Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study., Ann Rheum Dis, 74(2), 389-395, 2015
  118. Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus, RHEUMATOLOGY, 54(3), 405-412, 2015
  119. ★, A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study, MODERN RHEUMATOLOGY, 25(3), 344-349, 2015
  120. Combination therapy for early rheumatoid arthritis: a treatment holiday perspective., Expert Rev Clin Pharmacol, 8(1), 115-122, 2015
  121. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia, MODERN RHEUMATOLOGY, 25(4), 609-614, 2015
  122. Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis., Mod Rheumatol, 25(5), 672-678, 2015
    Link to Paper Search Results by DOI
  123. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry., Arthritis Res Ther, 17, 74, 2015
  124. Decreased Expression of Innate Immunity-Related Genes in Peripheral Blood Mononuclear Cells from Patients with IgG4-Related Disease., PLoS One, 10, e0126582, 2015
  125. ★, Serum 14-3-3 eta level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab, ARTHRITIS RESEARCH & THERAPY, 17, 280, 2015
  126. Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim analysis of 32 patients for 24 weeks, Mod Rheumatol, 25(2), 187-193, 2015
  127. Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis, MODERN RHEUMATOLOGY, 25(5), 672-678, 2015
  128. JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients, ARTHRITIS & RHEUMATOLOGY, 67, 2015
  129. 14-3-3 eta Positive Status and Higher Titres Are Associated with More Severe RA, ARTHRITIS & RHEUMATOLOGY, 67, 2015
  130. Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim analysis of 32 patients for 24 weeks, MODERN RHEUMATOLOGY, 25(2), 187-193, 2015
  131. Combination therapy for early rheumatoid arthritis: a treatment holiday perspective, EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 8(1), 115-122, 2015
  132. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry, ARTHRITIS RESEARCH & THERAPY, 17, 2015
  133. Imaging assessment of bone and cartilage destruction in rheumatoid arthritis, Clin Calcium, 25(12), 1777-1785, 2015
  134. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study, MODERN RHEUMATOLOGY, 24(1), 42-51, 2014
  135. Efficacy and safety of reducing duration of infliximab infusion, MODERN RHEUMATOLOGY, 24(2), 275-280, 2014
  136. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events, RHEUMATOLOGY, 53(5), 914-918, 2014
  137. Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan, MODERN RHEUMATOLOGY, 24(3), 464-470, 2014
  138. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia (R) as Biological Intensive Treatment for RA (ORBIT) study, MODERN RHEUMATOLOGY, 24(5), 754-762, 2014
  139. Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjogren Syndrome and Healthy Controls., ARTHRITIS & RHEUMATOLOGY, 66, S1225-S1225, 2014
  140. 14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies, ARTHRITIS & RHEUMATOLOGY, 66(12), 3537-3537, 2014
  141. Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis, DRUGS, 74(18), 2129-2139, 2014
  142. Validation of different sets of criteria for the diagnosis of Sjogren's syndrome in Japanese patients, MODERN RHEUMATOLOGY, 23(2), 219-225, 2013
  143. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs, MODERN RHEUMATOLOGY, 23(2), 284-296, 2013
  144. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology, MODERN RHEUMATOLOGY, 23(2), 297-303, 2013
  145. Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjogren's syndrome, MODERN RHEUMATOLOGY, 23(2), 401-405, 2013
  146. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study, RHEUMATOLOGY, 52(7), 1202-1207, 2013
  147. Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA (R) DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors, ARTHRITIS AND RHEUMATISM, 65, S616-S617, 2013
  148. Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?, CLINICAL THERAPEUTICS, 35(12), 2028-2035, 2013
  149. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study, ARTHRITIS RESEARCH & THERAPY, 15(5), 2013
  150. Discontinuation of biologics in patients with rheumatoid arthritis., Clin Exp Rheumatol, 2013
  151. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study), MODERN RHEUMATOLOGY, 22(3), 327-338, 2012
  152. A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/beta(2) glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies, MODERN RHEUMATOLOGY, 22(5), 769-773, 2012
  153. Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results., ARTHRITIS AND RHEUMATISM, 64(10), S333-S333, 2012
  154. A Multi-Biomarker Disease Activity (VECTRA (TM) DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab., ARTHRITIS AND RHEUMATISM, 64(10), S897-S897, 2012
  155. Correlation of A Multi-Biomarker Disease Activity (VECTRA (TM) DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib., ARTHRITIS AND RHEUMATISM, 64(10), S914-S915, 2012
  156. A Multi-Biomarker Disease Activity (VECTRA (TM) DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab, ARTHRITIS AND RHEUMATISM, 64(10), S1130-S1130, 2012
  157. Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy, ANNALS OF THE RHEUMATIC DISEASES, 71(12), 2058-U179, 2012
  158. Steroid psychosis in a polyarteritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally, ANNALS OF GENERAL PSYCHIATRY, 11, 2012
  159. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: V. Evaluation; 2. Evaluation of joint destruction by plain X-ray in rheumatoid arthritis., Nihon Naika Gakkai Zasshi, 101(10), 2893-2898, 2012
  160. A Novel Multi-Biomarker Disease Activity Score (Vectra (TM) DA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study, ARTHRITIS AND RHEUMATISM, 63(10), S132-S132, 2011
  161. Tofacitinib Reduces Interferon-gamma and Interleukin-17 Production From CD4+T Cells in Patients with Rheumatoid Arthritis., ARTHRITIS AND RHEUMATISM, 63(10), S496-S496, 2011
  162. A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study, ARTHRITIS AND RHEUMATISM, 63(10), S630-S630, 2011
  163. A Multi-Biomarker Disease Activity Score (Vectra (TM) DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy, ARTHRITIS AND RHEUMATISM, 63(10), S878-S878, 2011
  164. Discontinuation of Adalimumab Without Functional and Structural Progress After Attaining Remission in Patients with Rheumatoid Arthritis, ARTHRITIS AND RHEUMATISM, 63(10), S962-S962, 2011
  165. Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis, CLINICA CHIMICA ACTA, 407(1-2), 25-29, 2009
  166. A case of pulmonary asbestosis presenting with temporal arteritis involving multiple medium-sized vessels, MODERN RHEUMATOLOGY, 18(1), 100-104, 2008
  167. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease., Rheumatology (Oxford), 45, 1046-1047, 2006
  168. Neutropenic enterocolitis in lung cancer: a report of two cases and a review of the literature., Intern Med,, 44, 467-470, 2005
  169. Myocardial dysfunction in a patient with adult-onset Still's disease (AOSD)., Clin Exp Rheumatol,, 22, 506-507, 2004

Invited Lecture, Oral Presentation, Poster Presentation

  1. Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –, Hirata S, Omoto T, Kohno H, Watanabe H, Yukawa K, Tokunaga T, Kuranobu T, Oi T, Yoshida Y, Sugimoto T, Mokuda S, Oda K, Nojima T, Sugiyama E, ACR/ARHP Annual Meeting (ACR 2019), 2019/11/08, Without Invitation, English
  2. Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids, Shintaro Hirata, Kei Araki, Hiroki Kohno, Kazutoshi Yukawa, Tadahiro Tokunaga, Tatsuomi Kuranobu, Katsuhiro Oi, Yusuke Yoshida, Tomohiro Sugimoto, Keisuke Oda, Takaki Nojima, Eiji Sugiyama, ACR/ARHP Annual Meeting (ACR 2018), 2018/10/19, Without Invitation, English
  3. Optimisation of methotrexate dose induced successful reduction of glucocorticoids without impaired disease control in patients with rheumatoid arthritis, S. Hirata, T. Kondo, K. Yukawa, T.Tokunaga, T.Kuranobu, K. Oi, Y. Yoshida, M. Funaki, K. Oda, T. Nojima, E. Sugiyama, Annual European Congress of Rheumatology (EULAR 2018), 2018/06/13, Without Invitation, English
  4. Multicenter 14-3-3ETA biomarker reproducibility; the japanese experience, S. Hirata,M. Kaneda,T. Isayama,Y. Gu,A. Marott,W. P. Maksymowyc,Y. Tanaka, Annual European Congress of Rheumatology (EULAR 2017), 2017/06/14, Without Invitation, English
  5. 14-3-3ETA predicts joint damage progression and flaring after adalimumab discontinuation, S. Hirata,M. Kaneda,T. Isayama,Y. Gu,A. Marott,W. P. Maksymowyc,Y. Tanaka, Annual European Congress of Rheumatology (EULAR 2017), 2017/06/14, Without Invitation, English
  6. Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score, Shintaro Hirata,Xingbin Wang,CC Hwang,Ippei Miyagawa,Satoshi Kubo,Kazuhisa Nakano,Shingo Nakayamada,Kazuyoshi Saito,Nadine A. Defranoux,Yoshiya Tanaka, 2016/11/11, Without Invitation, English
  7. Lower Baseline 14-3-3eta Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients, Shintaro Hirata,Anthony Marotta,Kentaro Hanami, and Yoshiya Tanaka, 2016/11/11, Without Invitation, English
  8. Predictive Value of The Multi-Biomarker Disease Activity (MBDA) Score for Flare and Sustained Remission in The Honor Study, S.Hirata,S.Tang,C.C. Hwang,I. Miyagawa, S. Kubo,K. Nakano,S. Nakayamada,K. Saito, N.A. Defranoux,Y. Tanaka, 2016/06/08, Without Invitation, English
  9. Baseline Serum 14-3-3 ETA Independently Predicts Clinically Important Improvements in HAQ-DI in Patients with Rheumatoid Arthritis Treated with Tocilizumab, S.Hirata,K. Hanami,A. Marotta,Y. Tanaka, 2016/06/08, Without Invitation, English
  10. BAnti-JAK Is Anti-Fibrotic in Patients with Rheumatoid Arthritis, S. Hirata,N.S. Gudmann,S. Kubo,M. Karsdal,A.C. Bay-Jensen,Y. Tanaka, 2016/06/08, Without Invitation, English

Awards

  1. 2015/04/23, International Workshop Award, Japan College of Rheumatology

External Funds

Acceptance Results of Competitive Funds

  1. Practical Research Project for Allergic Diseases and Immunology, 2022//0/4/, 2023//0/3/
  2. Promoting Clinical Trials for Development of New Drugs and Medical Devices, 2022//0/4/, 2023//0/3/
  3. Practical Research Project for Allergic Diseases and Immunology, 2021/06/30, 2022/03/31
  4. Promoting Clinical Trials for Development of New Drugs and Medical Devices, 2021/04/01, 2022/03/31
  5. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2019, 2021
  6. 2018, 2020
  7. 2016
  8. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2016, 2018

Social Activities

History as Peer Reviews of Academic Papers

  1. 2022, Rheumatology and Therapy, Others, 5
  2. 2023, Immunological Medicine , Others, 3
  3. 2023, International Journal of Rheumatic Diseases , Others, 3
  4. 2023, Modern Rheumatology Case Reports , Others, 2
  5. 2023, Modern Rheumatology , Others, 4
  6. 2023, Rheumatology and Therapy , Others, 4
  7. 2023, Rheumatology , Others, 10
  8. 2022, Clinical Rheumatology, Others, 4
  9. 2022, Scandinavian Journal of Rheumatology, Others, 1
  10. 2022, Arthritis Research & Therapy, Others, 1
  11. 2022, International Journal of Rheumatic Diseases, Others, 2
  12. 2022, Modern Rheumatology Case Reports, Others, 1
  13. 2021, Rheumatology and Therapy, Others, 3
  14. 2021, International Journal of Rheumatic Diseases, Others, 2
  15. 2021, Modern Rheumatology Case Reports, Others, 2
  16. 2021, Rheumatology International, Others, 1
  17. 2021, Rheumatology, Others, 11
  18. 2021, Modern Rheumatology, Others, 12
  19. 2021, Arthritis Research & Therapy, Others, 3
  20. 2021, Cytokine, Others, 2
  21. 2021, Clinical Rheumatology, Others, 1
  22. 2020, Rheumatology, Others, 4
  23. 2020, The Journal of Rheumatology, Others, 1
  24. 2020, Internal Medicine, Others, 2
  25. 2020, Plos One, Others, 1
  26. 2020, Modern Rheumatology, Others, 9
  27. 2020, Journal of Clinical Rheumatology, Others, 4
  28. 2020, International Journal of Rheumatic Diseases, Others, 2
  29. 2020, Modern Rheumatology Case Reports, Others, 3
  30. 2019, Plos One, Others, 1
  31. 2019, Arthritis Research & Therapy, Others, 3
  32. 2019, ACR Open Rheumatology, Others, 1
  33. 2019, International Journal of Rheumatic Diseases, Others, 3
  34. 2019, Journal of Clinical Rheumatology, Others, 2
  35. 2019, Modern Rheumatology, Others, 11
  36. 2019, Modern Rheumatology Case Reports, Others, 6
  37. 2019, Rheumatology, Others, 5
  38. 2019, Rheumatology International, Others, 3
  39. 2018, Modern Rheumatology, Others, 7
  40. 2018, BMJ Open, Others, 3
  41. 2018, Arthritis Research & Therapy, Others, 3
  42. 2018, Geriatrics & Gerontology International, Others, 3
  43. 2018, Rheumatology, Others, 2
  44. 2018, International Journal of Rheumatic Diseases, Others, 2
  45. 2018, Modern Rheumatology Case Reports, Others, 2
  46. 2018, Rheumatology International, Others, 1
  47. 2018, Arthritis Care & Research, Others, 1
  48. 2017, Modern Rheumatology, Others, 13
  49. 2017, Plos One, Others, 4
  50. 2017, The Journal of Rheumatology, Others, 2
  51. 2017, Rheumatology, Others, 1
  52. 2017, Journal of Bone and Mineral Metabolism, Others, 1
  53. 2017, Inflammation Research, Others, 1
  54. 2017, Rheumatology International, Others, 1
  55. 2017, Journal of Clinical Rheumatology, Others, 1
  56. 2017, Arthritis Care & Research, Others, 1
  57. 2016, Modern Rheumatology, Others, 8
  58. 2016, Rheumatology International, Others, 6
  59. 2016, Arthritis Care & Research, Others, 4
  60. 2016, Rheumatology, Others, 2
  61. 2016, Inflammation Research, Others, 2
  62. 2015, Modern Rheumatology, 5
  63. 2015, Rheumatology International, 4
  64. 2015, Internal Medicine, 4
  65. 2015, Arthritis Care & Research, 4
  66. 2015, Journal of Bone and Mineral Metabolism, 1
  67. 2014, Modern Rheumatology, 7
  68. 2014, Rheumatology International, 4
  69. 2014, Arthritis Care & Research, 3
  70. 2014, Internal Medicine, 2
  71. 2014, The Journal of Rheumatology, 1
  72. 2013, The Journal of Rheumatology, 1
  73. 2011, Modern Rheumatology, 1
  74. 2010, Modern Rheumatology, 1